Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism

European Journal of Clinical Pharmacology

Volumn 65, Issue 1, 2009, Pages 55-64

  Lou, Horng Yuan ^a   Chang, Chun Chao ^a   Sheu, Ming Thau ^a   Chen, Ying Chen ^a   Ho, Hsiu O ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b Taipei Medical University ^*  (Taiwan)

Author keywords

CYP2C19; Esomeprazole; GERD; Intragastric pH; Polymorphism

Indexed keywords

ESOMEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYP2C19 GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; GASTROESOPHAGEAL REFLUX; GENE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPTIMAL DRUG DOSE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID; STOMACH PH; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ARYL HYDROCARBON HYDROXYLASES; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; GENE FREQUENCY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; OMEPRAZOLE; PHENOTYPE; PILOT PROJECTS; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57849122924     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0552-0     Document Type: Article

References (26)

1. WC Orr 2005 Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management Eur J Gastroenterol Hepatol 17 113 120
2. P Lindberg D Keeling J Fryklund T Andersson P Lundborg E Carlsson 2003 Esomeprazole - enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion Aliment Pharmacol Ther 17 481 488
3. NJV Bell D Burget CW Howden J Wilkinson RH Hunt 1992 Appropriate acid suppression for the management of gastro-oesophageal reflux disease Digestion 51 Suppl. 1 59 67
4. K Adachi H Fujishiro T Katsube M Yuki M Ono A Kawamura 2001 Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis J Gastroenterol Hepatol 16 1191 6
5. PL Peghini PO Katz DO Castell 1998 Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects Gastroenterology 115 1335 1339
6. P Miner Jr PO Katz Y Chen M Sostek 2003 Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study Am J Gastroenterol 98 2616 2620
7. A Thomson C Claar-Nilsson G Hasselgren M Niazi K Rohss L Nyman 2000 Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration Gut 47 Suppl. 3 A63 Abstract
8. T Lind L Rydberg A Kyleback 2000 Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease Aliment Pharmacol Ther 14 861 867
9. K Röhss G Hasselgren H Hedenström 2002 Effect of esomeprazole 40 mg vs. omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease Dig Dis Sci 47 954 958
10. C Wilder-Smith K Röhss C Lundin H Rydholm 2000 Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg Gastroenterology 118 A22 23
11. C Wilder-Smith C Claar-Nilsson G Hasselgren K Röhss 2002 Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GORD J Gastroenterol Hepatol 17 Suppl. A612 Abstract
12. PO Katz DO Castell Y Chen T Andersson MB Sostek 2004 Intragastric acid suppression and pharmacokinelics of twice-daily esomeprazole: a randomized, three-way crossover study Aliment Pharmacol Ther 20 399 406
13. JP Galmiche S Bruley DES Varannes P Ducrotte S Sacher-Huvelin F Vavasseur 2004 Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers Aliment Pharmacol Ther 19 655 662
14. PL Peghini PO Katz NA Bracy DO Castell 1998 Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors Am J Gastroenterol 93 763 767
15. PO Katz C Anderson R Khoury DO Castell 1998 Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors Aliment Pharmacol Ther 12 1231 1234
16. T Katsube K Adachi A Kawamura K Amano Y Uchida M Watanabe Y Kinoshita 2000 Helicobacter pylori infection influences nocturnal gastric acid breakthrough Aliment Pharmacol Ther 14 1049 1056
17. CAM Stedman ML Barclay 2000 Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors Aliment Pharmacol Ther 14 963 978
18. M Hassan-Alin T Andersson M Niazi K Röhss 2005 A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects Eur J Clin Pharmacol 60 779 784
19. T Shimatani M Inoue T Kuroiwa J Xu H Mieno M Nakamura S Tazuma 2006 Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 Clin Pharmacol Therapeutics 79 144 1452
20. M Robinson 2004 The pharmacodynamics and pharmacokinetics of proton pump inhibitors - overview and clinical implications Aliment Pharmacol Ther 20 1 10
21. M Sugimoto T Furuta N Shirai M Kajimura A Hishida MO Sakurai T Ishizaki 2004 Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status Clin Pharmacol Ther 76 290 301
22. B-S Sheu A-W Kao H-C Cheng S-F Hunag T-W Chen C-C Lu J-J Wu 2005 Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism Aliment Pharmacol Ther 21 283 288
23. M Schwab U Klotz U Hofmann E Schaeffeler A Leodolter P Malfertheiner G Treiber 2005 Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data Clin Pharmacol Ther 78 627 634
24. SMF De Morais GR Wilkinson J Blaisdell K Nakamura UA Meyer JA Goldstein 1994 The major genetic defect responsible for the polymorphism of S- mephenytoin metabolism in humans J Biol Chem 269 15419 15422
25. K Adachi Y Komazawa H Fujishiro T Mihara M Ono M Yuki 2003 Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subject: effects of different regimens J Gastroenterol 38 830 835
26. Wagner JG (1979) Fundamentals of Clinical Pharmacokinetics, 2nd edn. Drug Intelligence Publications, Inc., Hamilton, IL, pp 36-7